Concurrent to development of more effective drugs for treatment of hepatitis C virus (HCV) infection, there has been an increase in the incidence of nonalcoholic fatty liver disease.
Data indicate that liver transplantation prolongs survival times of patient with acute hepatitis associated with alcoholic liver disease.
Dr David Goldberg and colleagues from Pennsylvania, USA compared data on disease prevalence in the population with data from liver transplantation waitlists to evaluate changes in the burden of liver disease in the United States.
The researchers collected data on the prevalence of HCV from the 2010 and 2013–2014 cycles of the National Health and Nutrition Examination Survey.
The team also collected data from the HealthCore Integrated Research Database on patients with cirrhosis and chronic liver failure from 2006 through 2014, and data on patients who received transplants from the United Network for Organ Sharing from 2003 through 2015.
|The percentage of patients on the waitlist or receiving liver transplants for NASH is increasing|
The researchers determined percentages of new waitlist members and transplant recipients with HCV infection, stratified by indication for transplantation, modeling each calendar year as a continuous variable using the Spearman rank correlation, nonparametric test of trends, and linear regression models.
In an analysis of data from the National Health and Nutrition Examination Survey, the team found that the proportion of patients with a positive HCV antibody who had a positive HCV RNA was 0.5.
The research team observed that this value was significantly lower than in 2010.
Data from the HealthCore database revealed significant changes over time in percentages of patients with compensated cirrhosis, chronic liver failure, and hepatocellular carcinoma (HCC).
Data from the United Network for Organ Sharing revealed that among patients new to the liver transplant waitlist, or undergoing liver transplantation, for chronic liver failure, there was a significant decrease in the percentage with HCV infection and increases in percentages of patients with nonalcoholic fatty liver disease or alcoholic liver disease.
The researchers observed that among patients new to the liver transplant waitlist or undergoing liver transplantation for HCC, proportions of those with HCV infection, nonalcoholic fatty liver disease, or alcoholic liver disease did not change between 2003 and 2015.
Dr Goldberg's team concludes, "In an analysis of 3 different databases, we found the proportion of patients on the liver transplant waitlist or undergoing liver transplantation for chronic HCV infection to be decreasing, and fewer patients to have cirrhosis or chronic liver failure."
"However, the percentages of patients on the waitlist or receiving liver transplants for NASH or alcoholic liver disease are increasing, despite different relative burdens of disease among the entire population of patients with cirrhosis."